Mereo BioPharma Group (MREO) to Release Quarterly Earnings on Wednesday

Mereo BioPharma Group (NASDAQ:MREO - Get Free Report) is anticipated to announce its Q1 2025 earnings results before the market opens on Wednesday, May 21st. Analysts expect the company to announce earnings of ($0.01) per share for the quarter.

Mereo BioPharma Group (NASDAQ:MREO - Get Free Report) last issued its earnings results on Tuesday, May 13th. The company reported ($0.02) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.01). On average, analysts expect Mereo BioPharma Group to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Mereo BioPharma Group Stock Performance

Shares of NASDAQ:MREO traded up $0.05 on Monday, hitting $2.29. The stock had a trading volume of 855,496 shares, compared to its average volume of 1,113,226. Mereo BioPharma Group has a twelve month low of $1.58 and a twelve month high of $5.02. The firm's 50 day moving average price is $2.31 and its 200-day moving average price is $2.95. The company has a market capitalization of $364.11 million, a price-to-earnings ratio of -32.71 and a beta of 0.53.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Goldman Sachs Group Inc. lifted its position in Mereo BioPharma Group by 0.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,125,920 shares of the company's stock valued at $4,783,000 after purchasing an additional 6,068 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Mereo BioPharma Group by 62.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,569,100 shares of the company's stock valued at $3,530,000 after purchasing an additional 604,200 shares during the period. Finally, Woodline Partners LP lifted its position in Mereo BioPharma Group by 53.2% during the 1st quarter. Woodline Partners LP now owns 947,986 shares of the company's stock valued at $2,133,000 after purchasing an additional 329,202 shares during the period. 62.83% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

MREO has been the topic of several recent analyst reports. JPMorgan Chase & Co. initiated coverage on shares of Mereo BioPharma Group in a research note on Thursday, March 27th. They issued an "overweight" rating and a $7.00 target price on the stock. Needham & Company LLC reiterated a "buy" rating and set a $7.00 price target on shares of Mereo BioPharma Group in a research report on Tuesday, May 13th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and set a $7.00 price target on shares of Mereo BioPharma Group in a research report on Tuesday, March 18th. Six research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Mereo BioPharma Group has a consensus rating of "Buy" and an average target price of $7.71.

About Mereo BioPharma Group

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors.